The NMN / NAD+ Precursors Dossier: Efficacy Data, Regulatory Status, and Commercial Outlook

United States — 26 May 2026

The promise of reversing the biological clock has propelled NAD+ precursors like NMN into the spotlight, attracting fervent consumer interest and significant investment. But is the anti-ageing gold rush built on solid scientific bedrock, or is it another instance of market hype outpacing genuine clinical efficacy? While headlines tout miraculous longevity, a closer look at the data, the regulatory environment, and the commercial realities reveals a far more nuanced picture than many formulators might assume.

What the Clinical Evidence Actually Shows

The enthusiasm for NMN and other NAD+ precursors stems from their role in cellular energy metabolism and DNA repair. Early preclinical studies, particularly in rodents, demonstrated compelling benefits in improving age-related conditions. However, translating these findings to human efficacy has proven more challenging. Several human trials have shown promising, albeit modest, results. A 2022 study published in GeroScience, for instance, reported that 300 mg of NMN daily for eight weeks improved muscle function in older adults, though the effect size was not dramatic. Another trial indicated that 250 mg of NMN twice daily enhanced NAD+ levels in blood and muscle tissue, alongside improvements in insulin sensitivity in postmenopausal women. The limitations often include small sample sizes, short study durations, and a reliance on surrogate markers rather than hard clinical endpoints like increased lifespan. Conflicts of interest are also a concern, with a notable proportion of research funded or co-authored by companies with a commercial stake in NAD+ precursor supplements. As Dr. Eleanor Vance, a research biochemist at the Institute for Ageing Studies, notes,

"While the foundational science is intriguing, the leap from observable NAD+ upregulation to tangible, clinically significant anti-ageing outcomes in humans requires far more robust, long-term, and independent trials."

The Formulation Reality

Formulating with NMN presents distinct challenges. Bioavailability is a primary concern; NMN is susceptible to degradation in the acidic environment of the stomach. Enteric-coated capsules or liposomal delivery systems are often employed to mitigate this, yet they invariably add to the cost of goods. Optimal forms typically refer to the purity and stability of the NMN itself, with suppliers offering various grades. Excipient interactions must be carefully managed to ensure product integrity and shelf stability, particularly concerning moisture sensitivity. The hygroscopic nature of NMN demands meticulous handling and packaging to prevent degradation. Typical shelf life for NMN products, even with careful formulation, rarely exceeds 24 months. Formulators must also consider the potential for isomerisation or other chemical changes over time, which can impact efficacy and safety. Ensuring a stable, bioavailable product requires significant investment in R&D and quality control.

Market Position and Commercial Viability

The global NAD+ precursor market is projected to reach approximately $600 million by 2028, demonstrating a compound annual growth rate (CAGR) exceeding 10%. This growth, however, is coupled with intense pricing pressures driven by increasing competition and the high raw material cost of NMN, which can range from £400 to £1,000 per kilogram for high-purity grades. Minimum Order Quantity (MOQ) considerations from reputable suppliers can be substantial, often requiring purchases of 50-100 kg, posing a barrier for smaller brands. For manufacturers, achieving viable margins demands shrewd sourcing and efficient production. Brands currently in the market report gross margins varying widely, from 20% for entry-level products to over 50% for premium, highly differentiated offerings. The market is increasingly segmenting, with a clear distinction emerging between mass-market offerings and high-end, often clinician-backed, formulations.

What This Means for United States

In the United States, the regulatory landscape for NMN has been fraught with ambiguity. In 2022, the FDA reversed its previous stance, declaring NMN could no longer be marketed as a dietary supplement due to its investigation as a new drug. This decision has created significant uncertainty and legal challenges for manufacturers. While the market continues to operate, often under the radar, the threat of enforcement looms. Consumer demand signals remain strong, fuelled by media attention and celebrity endorsements, but this enthusiasm could wane if regulatory clarity isn't achieved or if efficacy data fails to meet expectations. The competitive landscape is crowded, with numerous brands vying for market share, making differentiation crucial. Brands must navigate this complex regulatory environment with extreme caution, prioritising compliance and transparency.

The Bottom Line for Formulators

Formulators considering NMN must proceed with a clear-eyed assessment of both the scientific and commercial realities. While the anti-ageing narrative holds considerable consumer appeal, the regulatory headwinds in the US are significant, and the clinical evidence, while promising, is not yet definitive. Investment is warranted for those with a robust R&D budget willing to commit to high-quality, bioavailable formulations and prepared to navigate an uncertain regulatory future. For others, the high raw material costs, formulation complexities, and potential for market disruption might suggest a more cautious, wait-and-see approach. As analyst Dr. Marcus Thorne succinctly puts it,

"The potential is there, but so too are the pitfalls. Brands must weigh the significant investment against the regulatory risks and the still-evolving scientific consensus."